Merck Teams With Lycera In Second Autoimmune Deal
This article was originally published in The Pink Sheet Daily
The Michigan-based biotech says the latest discovery and development deal with Merck is validation of its ongoing work with the Big Pharma in the field of autoimmune diseases.
You may also be interested in...
Emerging Markets Earnings Roundup: Merck, Pfizer And Amgen (Part 3)
Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
Lycera Corp. develops small-molecule immunomodulators. Its lead benzodiazapene-based compounds have shown efficacy in animal models of lupus, psoriasis, rheumatoid arthritis, inflammatory bowel disease and transplant rejection. Lycera also recently acquired a program targeting the TH17 pathway, which controls production of IL-17, a pro-inflammatory cytokine increasingly considered critical to inflammation and autoimmune disease.